Organic Cation Transporter
Organic Cation Transporter - Related Videos
12:48
Measuring Cation Transport by Na,K- and H,K-ATPase in Xenopus Oocytes by Atomic Absorption Spectrophotometry: An Alternative to Radioisotope Assays
0 Views •
Cited by 7 •
2013
We describe a method to quantify the activity of K+-countertransporting P-type ATPases by heterologous expression of the enzymes in Xenopus oocytes and measuring Rb+ or Li+ uptake into individual cells by atomic absorption spectrophotometry. The method is a sensitive and safe alternative to radioisotope flux experiments facilitating complex kinetic studies.
09:02
Characterization of Intra-Cartilage Transport Properties of Cationic Peptide Carriers
0 Views •
Cited by 22 •
2020
This protocol determines equilibrium uptake, depth of penetration and non-equilibrium diffusion rate for cationic peptide carriers in cartilage. Characterization of transport properties is critical for ensuring an effective biological response. These methods can be applied for designing an optimally charged drug carriers for targeting negatively charged tissues.
13:16
A Whole Cell Bioreporter Approach to Assess Transport and Bioavailability of Organic Contaminants in Water Unsaturated Systems
0 Views •
Cited by 5 •
2014
A whole cell bioreporter assay with Burkholderia sartisoli RP037-mChe was developed to detect fractions of an organic contaminant (i.e., fluorene) available for bacterial degradation after active transport by mycelia bridging air-filled pores in a water unsaturated model system.
10:23
Synthesis of Cationized Magnetoferritin for Ultra-fast Magnetization of Cells
0 Views •
Cited by 1 •
2016
A protocol for the synthesis and cationization of cobalt-doped magnetoferritin is presented, as well as a method to rapidly magnetize stem cells with cationized magnetoferritin.
08:30
Monovalent Cation Doping of CH3NH3PbI3 for Efficient Perovskite Solar Cells
0 Views •
Cited by 31 •
2017
Here, we present a protocol to adjust the properties of solution-processed CH3NH3PbI3 through the incorporation of monovalent cation additives in order to achieve highly efficient perovskite solar cells.
FAQs
OCT-mediated movement is typically electrogenic, meaning it depends on the electrical gradient across the cell membrane. Unlike primary active transporters, these proteins do not directly hydrolyze ATP to move substrates. Consequently, changes in membrane potential can influence the uptake of positively charged compounds, helping determine how efficiently drugs enter cells such as hepatocytes or renal epithelial cells.
OCT1 and OCT2 connect circulating drug concentrations with tissue-specific uptake. OCT1 contributes to entry of cationic substances from blood into hepatocytes, where hepatic metabolism may follow, while OCT2 supports uptake into renal epithelial cells involved in renal secretion. Their locations therefore help determine whether a compound is processed predominantly through hepatic or renal pathways.
Transporter inhibition can reduce cellular uptake of cationic drugs, while genetic variation can change transporter activity between individuals. Either mechanism may alter drug exposure by affecting hepatic metabolism or renal secretion. The resulting differences can influence therapeutic effects and toxicity, making OCT activity relevant when interpreting variable responses or anticipating altered pharmacological outcomes.
Pharmacologists consider whether one drug inhibits OCT-mediated handling of another cationic compound. Reduced transporter activity may change the compound's entry into hepatocytes or renal epithelial cells, which can modify metabolism, secretion, and overall exposure. This assessment helps identify interaction risks before selecting dosing strategies, particularly when altered exposure could increase toxicity or change treatment effects.
Studies of OCT activity can indicate how strongly a cationic drug depends on hepatic uptake, renal epithelial uptake, or both. Those findings help connect transporter function with downstream metabolism and renal secretion. In pharmacology, this information supports interpretation of clearance pathways and clarifies why changes in transporter activity may produce different exposure profiles across drugs.
OCT information becomes especially useful when a drug's exposure may be altered by transporter inhibition or inherited variation. Linking transporter activity with hepatic metabolism and renal secretion can help pharmacologists anticipate changes in concentration, therapeutic response, or toxicity. These insights support dosing strategies that account for drug-drug interaction risks and differences among individuals.